News

PUBLICATIONS

Detection of rare prostate cancer cells in human urine offers prospect of non-invasive diagnosis. Sayyadi, N, Justiniano, I, Wang, Y, Zheng, X, Zhang, W, Jiang, L, Polikarpov, DM, Willows, RD, Gillatt, D, Campbell, D, Walsh, BJ, Yuan, J, Lu, Y, Packer, NH, Wang, Y & Piper, JA 2022. Scientific Reports, vol. 12, no. 1, 18452.

Cancer-derived small extracellular vesicles: emerging biomarkers and therapies for pancreatic ductal adenocarcinoma diagnosis/prognosis and treatment. Zhang, W, Campbell, DH, Walsh, BJ, Packer, NH, Liu, D & Wang, Y 2022. Journal of Nanobiotechnology, vol. 20, no. 1, 446.

Phenotypic profiling of pancreatic ductal adenocarcinoma plasma-derived small extracellular vesicles for cancer diagnosis and cancer stage prediction: a proof-of-concept study. Wei Zhang, Ling Wang, Dan Li, Douglas H. Campbell, Bradley J. Walsh, et al. RSC. 2022.

Development and evaluation of the MiCheck test for aggressive prostate cancer. Shore ND, Pieczonka CM, Henderson RJ, Bailen JL, Saltzstein DR, Concepcion RS, et al. Urol Oncol Semin Orig Investig. 2020.

A comparison of prostate health index, total PSA, %free PSA, and proPSA in a contemporary US population—The MiCheck-01 prospective trial Shore ND, Pieczonka CM, Henderson RJ, Bailen JL, Saltzstein DR, Concepcion RS, et al. Urol Oncol. 2020.

The Role of Glypican-1 in the Tumour Microenvironment. Lund ME, Campbell DH, Walsh BJ. Adv Exp Med Biol. 2020.

Detection of glypican-1 (GPC-1) expression in urine cell sediments in prostate cancer. Campbell DH, Lund ME, Nocon AL, Cozzi PJ, Frydenberg M, De Souza P, et al. PLoS One. 2018.

Development of a reliable assay to measure glypican-1 in plasma and serum reveals circulating glypican-1 as a novel prostate cancer biomarker. Levin RA, Lund ME, Truong Q, Wu A, Shore ND, Saltzstein DR, et al. Oncotarget. 2018.

Glypican-1 as a biomarker for prostate cancer: Isolation and characterization. Truong Q, Justiniano IO, Nocon AL, Soon JT, Wissmueller S, Campbell DH, et al. J Cancer. 2016.